SCHEMBL12412503

SCHEMBL12412503

C=C(C)C(=O)Oc1ccc(C(=O)C(O)c2cc(OC)cc(OC)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.49
MAPT P10636 2/20 0.44
KMT2A Q03164 6/20 0.40
ATM Q13315 1/20 0.40
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 2/20 0.38
MEN1 O00255 2/20 0.38
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TP53 P04637 1/20 0.38
CYP3A4 P08684 1/20 0.38
GAA P10253 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RXRA P19793 1/20 0.36
POLB P06746 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21504942 0.82 ELANE (0.52) ELANEMAPTKMT2AATMALDH1A1
SCHEMBL9802271 0.82 ELANE (0.64) ELANEMAPTKMT2AATMALDH1A1
SCHEMBL9802263 0.80 ELANE (0.64) ELANEMAPTKMT2AATMALDH1A1
Carbamic Acid SCHEMBL23407287 0.79 CA1 (0.50) MAPTKMT2AALDH1A1CYP1A2MEN1
SCHEMBL12412504 0.78 ABCG2 (0.44) KMT2AALDH1A1CYP1A2MEN1NPC1
Acetic Acid SCHEMBL3368380 0.77 CES2 (0.56) MAPTKMT2AALDH1A1MEN1NPC1
SCHEMBL139044 0.77 CES2 (0.59) MAPTKMT2AALDH1A1MEN1NPC1
SCHEMBL14181968 0.76 CES2 (0.48) KMT2AALDH1A1MEN1GAARXRA
SCHEMBL9802818 0.76 ELANE (0.52) ELANEKMT2AALDH1A1CYP1A2MEN1
SCHEMBL450454 0.76 ELANE (0.61) ELANEMAPTKMT2AATMALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160136286-A1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-05-19 US disclosed
US-20160136286-A1 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-05-19 US disclosed
US-9271928-B2 Drug delivery composition THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-03-01 US disclosed
US-9271928-B2 Drug delivery composition THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2016-03-01 US disclosed
US-20110165114-A1 DRUG DELIVERY COMPOSITION QUEEN'S UNIVERSITY OF BELFAST, THE (GB) 2011-07-07 US disclosed
US-20110165114-A1 DRUG DELIVERY COMPOSITION QUEEN'S UNIVERSITY OF BELFAST, THE (GB) 2011-07-07 US disclosed
WO-2009147372-A2 DRUG DELIVERY COMPOSITION THE QUEEN'S UNIVERSITY OF BELFAST (GB) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165114-A1 DRUG DELIVERY COMPOSITION ECPAS, ABCB11, ABCB1 ELANE 2228/4885MAPT 19/4885KMT2A 2916/4885
US-20160136286-A1 DRUG DELIVERY COMPOSITION ECPAS, ABCB11, ABCB1 ELANE 2228/4885MAPT 19/4885KMT2A 2916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.